Significance of age‑associated quality of life in patients with stage&nbsp;IV breast cancer who underwent endocrine therapy in Japan

Takada,Koji; Kashiwagi,Shinichiro; Asano,Yuka; Goto,Wataru; Morisaki,Tamami; Takahashi,Katsuyuki; Shibutani,Masatsune; Amano,Ryosuke; Takashima,Tsutomu; Tomita,Shuhei; Hirakawa,Kosei; Ohira,Masaichi

doi:10.3892/ol.2020.12041

Significance of age‑associated quality of life in patients with stage IV breast cancer who underwent endocrine therapy in Japan

Authors:
- Koji Takada
- Shinichiro Kashiwagi
- Yuka Asano
- Wataru Goto
- Tamami Morisaki
- Katsuyuki Takahashi
- Masatsune Shibutani
- Ryosuke Amano
- Tsutomu Takashima
- Shuhei Tomita
- Kosei Hirakawa
- Masaichi Ohira
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Hepato‑Biliary‑Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: August 31, 2020 https://doi.org/10.3892/ol.2020.12041
Article Number: 180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, when determining treatment regimens, there is an emphasis on the quality of life (QOL), in addition to treatment efficacy. Especially in hormone receptor‑positive breast cancer with distant metastases, unless death is imminent, a common first‑line treatment is endocrine therapy, which has fewer side effects. In the present study, the differences in QOL were evaluated based on the age and prognostic indicators of 46 patients with hormone receptor‑positive breast cancer with distant metastases (stage IV), who received first‑line endocrine therapy at the Osaka City University Hospital (Osaka, Japan) between November 2007 and November 2016. QOL score before and after endocrine therapy was retrospectively analyzed, using the Quality of Life Questionnaire for Cancer Patients Treated with Anti‑Cancer Drugs‑Breast (QOL‑ACD‑B). There was no significant association between age and any of the clinicopathological features investigated. However, the QOL score of the elderly patient group was significantly higher compared with that of the younger group in the ‘Satisfaction with treatment and coping with disease’ subcategory (P=0.008). The QOL score of the younger age group in the same subcategory was significantly improved by the treatment (P=0.013). The patients that had an increased overall QOL score 3 months after treatment initiation had a significant extension of progression‑free survival (PFS) rate compared to the patients with decreased or no change in QOL (P=0.032). In conclusion, psychological stress was more prominent in younger patients with stage IV breast cancer treated with hormonal therapy compared with elderly patients. Importantly, improving QOL within the 3 months after treatment initiation could lead to longer PFS rate.

View Figures

View References

1	Saracci R: The World Health Organisation needs to reconsider its definition of health. BMJ. 314:1409–1410. 1997. View Article : Google Scholar : PubMed/NCBI
2	Maisey NR, Norman A, Watson M, Allen MJ, Hill ME and Cunningham D: Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 38:1351–1357. 2002. View Article : Google Scholar : PubMed/NCBI
3	Kaasa S, Mastekaasa A and Lund E: Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol. 15:235–242. 1989. View Article : Google Scholar : PubMed/NCBI
4	Gotay CC, Kawamoto CT, Bottomley A and Efficace F: The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 26:1355–1363. 2008. View Article : Google Scholar : PubMed/NCBI
5	Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J and Pater JL: Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 6:151–158. 1997. View Article : Google Scholar : PubMed/NCBI
6	Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 339:974–984. 1998. View Article : Google Scholar : PubMed/NCBI
7	McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, : Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 97:1180–1184. 2005. View Article : Google Scholar : PubMed/NCBI
8	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K and Shimozuma K: Development of quality of life questionnaire in Japan: Quality of life assessment of cancer patients receiving chemotherapy. Psychooncology. 8:355–363. 1999. View Article : Google Scholar : PubMed/NCBI
10	Otsuka S, Watanabe N, Sasaki Y and Shimojima R: Postoperative courses of breast reconstruction using inferior adipofascial tissue repair. Breast Cancer. 22:570–577. 2015. View Article : Google Scholar : PubMed/NCBI
11	Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A and Muss H: Breast cancer in the elderly. J Clin Oncol. 25:1882–1890. 2007. View Article : Google Scholar : PubMed/NCBI
12	Louwman WJ, Vulto JC, Verhoeven RH, Nieuwenhuijzen GA, Coebergh JW and Voogd AC: Clinical epidemiology of breast cancer in the elderly. Eur J Cancer. 43:2242–2252. 2007. View Article : Google Scholar : PubMed/NCBI
13	Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, Nolè F, de Braud F, Orlando L, Leonardi MC, et al: Breast carcinoma in elderly women: Features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer. 101:1302–1310. 2004. View Article : Google Scholar : PubMed/NCBI
14	Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, et al: Management of breast cancer in elderly individuals: Recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 8:1101–1115. 2007. View Article : Google Scholar : PubMed/NCBI
15	Shimozuma K, Sonoo H, Ichihara K and Tanaka K: The prognostic value of quality-of-life scores: Preliminary results of an analysis of patients with breast cancer. Surg Today. 30:255–261. 2000. View Article : Google Scholar : PubMed/NCBI
16	Schou I, Ekeberg O, Sandvik L, Hjermstad MJ and Ruland CM: Multiple predictors of health-related quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population. Qual Life Res. 14:1813–1823. 2005. View Article : Google Scholar : PubMed/NCBI
17	Watters JM, Yau JC, O'Rourke K, Tomiak E and Gertler SZ: Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer. Ann Oncol. 14:1744–1750. 2003. View Article : Google Scholar : PubMed/NCBI
18	Akin S, Can G, Durna Z and Aydiner A: The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 12:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
19	Hurwitz N: Predisposing factors in adverse reactions to drugs. Br Med J. 1:536–539. 1969. View Article : Google Scholar : PubMed/NCBI
20	Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002. View Article : Google Scholar : PubMed/NCBI
21	Levy M, Kewitz H, Altwein W, Hillebrand J and Eliakim M: Hospital admissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol. 17:25–31. 1980. View Article : Google Scholar : PubMed/NCBI
22	Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, et al: A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 54:1119–1124. 2006. View Article : Google Scholar : PubMed/NCBI
23	Mols F, Vingerhoets AJ, Coebergh JW and van de Poll-Franse LV: Quality of life among long-term breast cancer survivors: A systematic review. Eur J Cancer. 41:2613–2619. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chee Chean D, Kuo Zang W, Lim M and Zulkefle N: Health Related Quality of Life (HRQoL) among breast cancer patients receiving chemotherapy in Hospital Melaka: Single Centre Experience. Asian Pac J Cancer Prev. 17:5121–5126. 2016.PubMed/NCBI
25	Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M and Cortes J: A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. Breast. 23:656–662. 2014. View Article : Google Scholar : PubMed/NCBI
26	Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU and Hortobagyi GN: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 73:2157–2167. 1994. View Article : Google Scholar : PubMed/NCBI
27	Tsuji W, Teramukai S, Ueno M, Toi M and Inamoto T: Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer. 21:86–95. 2014. View Article : Google Scholar : PubMed/NCBI
28	Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M and Forbes JF: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol. 10:1833–1838. 1992. View Article : Google Scholar : PubMed/NCBI
29	Spiegel D, Bloom JR, Kraemer HC and Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 2:888–891. 1989. View Article : Google Scholar : PubMed/NCBI
30	Spiegel D, Sephton SE, Terr AI and Stites DP: Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways. Ann N Y Acad Sci. 840:674–683. 1998. View Article : Google Scholar : PubMed/NCBI
31	Kuchler T, Bestmann B, Rappat S, Henne-Bruns D and Wood-Dauphinee S: Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 25:2702–2708. 2007. View Article : Google Scholar : PubMed/NCBI